First-line tagraxofusp induces durable responses with prolonged survival in adults younger than 50 years with blastic plasmacytoid dendritic cell neoplasm: Post hoc analysis of a phase 2 trial. [PDF]
Br J HaematolBritish Journal of Haematology, Volume 207, Issue 6, Page 2592-2596, December 2025.
Stein AS +7 more
europepmc +2 more sources
Impressive Skin and Systemic Response Despite Patient Underestimation and Delayed Diagnosis of Blastic Plasmacytoid Dendritic Cell Neoplasm. [PDF]
Case Rep HematolBlastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy derived from precursors of plasmacytoid dendritic cells (pDCs), most frequently presenting with cutaneous involvement and often progressing to bone marrow (BM), lymph node, and central nervous system (CNS) infiltration.
Pacini E +7 more
europepmc +2 more sources
Tagraxofusp: Expanding Therapeutic Horizons in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) [PDF]
, 2023 Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematological malignancy with limited treatment options. The development of tagraxofusp, a CD123-directed recombinant fusion protein, has revolutionized the management of BPDCN.
Dr sugreev Dwivedi Anuj Dwivedi +1 more
core +1 more source
Analysis of Tagraxofusp Activity in AML-Pdc As a Single Agent and in Combination with BCL2 Inhibitors [PDF]
, 2023 peer reviewed Acute myeloid leukemia with increased plasmacytoid dendritic cells (AML-PDC) is a new leukemia recently clarified in the classification of hematological diseases (WHO 2022).
Fredon, Maxime +10 more
core +1 more source
Acute Myeloid Leukemia With Plasmacytoid Differentiating Cutaneous Lesions: A Case of Double Identity or Active Transformation. [PDF]
EJHaemABSTRACT Introduction Acute myeloid leukemia (AML) with plasmacytoid dendritic cell differentiation (pDC‐AML) is a newly described subtype of leukemia with features resembling blastic plasmacytoid dendritic cell neoplasm (BPDCN). Case Presentation Herein, we present a case of pDC‐AML in which bone marrow findings were best classified as AML, whereas ...
Lee BJ +5 more
europepmc +2 more sources
Blastic plasmacytoid dendritic cell neoplasm: a short review and update
Dermatology Reports, 2023 Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic neoplasm (less than 1% of primary cutaneous lymphomas and acute leukemia) with a highly aggressive clinical course and frequent skin, bone marrow and central nervous system (CNS)
Cesare Massone +3 more
doaj +1 more source
Tagraxofusp in myeloid malignancies
Hematological Oncology, 2023 Abstract Tagraxofusp (or SL‐401) is a recombinant molecule composed of human interleukin‐3 that binds CD123 on neoplastic cells fused to a truncated diphtheria toxin (DT). Tagraxofusp's most significant success has come from studies involving patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), an aggressive disease ...
Antonella Bruzzese +10 more
openaire +3 more sources